{
    "clinical_study": {
        "@rank": "82280", 
        "acronym": "ALTN/STS", 
        "arm_group": {
            "arm_group_label": "Anlotinib Hydrochloric Capsule", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "Anlotibib (ALTN) is a kind of innovative medicines approved by State Food and Drug\n      Administration\uff08SFDA\uff09 which was researched by Jiangsu Chia-tai Tianqing Pharmaceutical Co.,\n      Ltd.\n\n      ALTN is a kinase inhibitor of receptor tyrosine with multi-targets, especially for VEGFR2\n      and VEGFR3. It has the obvious resistance to new angiogenesis. The protocol is to explore\n      ALTN for the effectiveness of advanced soft tissue sarcoma and security."
        }, 
        "brief_title": "A Phase II Study of Anlotinib Hydrochloric Capsule in STS Patients", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Cancer", 
        "condition_browse": {
            "mesh_term": "Sarcoma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  1.Faild in introditional treatmeat, Mainly includes:MFH/liposarcoma/leiomyosarcoma/SS\n             and others(MPNST/Fibrosarcoma/CCS/ASPS/AS/ES; 2.Receiveed at least one chemotherapy\n             regimens treatment; 3.18-70years, ECOG:0-2,Expected survival period >3 months;\n             4.HB\u2265100g/L,ANC(Absolute Neutrophil Count) \u22651.5\u00d7109/L\uff1bPLT\n\n               -  80\u00d7109/L ,BIL/Cr in normal range,ALT/AST(aspartate aminotransferase\n                  )\u22641.5*ULN(for hepatic metastases,ALT/AST(aspartate aminotransferase )\u22645*ULN)\n                  ;TG\u2264 3.0mmol/L\uff0ccholesterol\u22647.75mmol/L; LVEF\n\n               -  LLN. 5.Used contraceptive during the study and after 6 months; 6.Volunteer.\n\n        Exclusion Criteria:\n\n          -  1. Received vascular endothelial growth inhibitor type of targeted therapy; 2.With\n             the second cancer; 3.Participated in other clinical trials in four weeks; 4.Received\n             in other radiotherapy or chemotherapy treatment in four weeks; 5.AE>1 6.Has influence\n             of oral drugs; 7.Brain metastases, spinal cord compression, cancerous meningitis;\n             8.Any serious or failed to control the disease 9.Artery/venous thrombotic;\n             10.Coagulant function abnormality; 11.Arteriovenous thrombosis event; 12.Hitory of\n             psychiatric drugs abuse or a mental disorder; 13.Immunodeficiency history;\n             14.Concomitant diseases."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01878448", 
            "org_study_id": "ALTN-02-II"
        }, 
        "intervention": {
            "arm_group_label": "Anlotinib Hydrochloric Capsule", 
            "intervention_name": "Anlotinib Hydrochloric Capsule", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 15, 2013", 
        "location": [
            {
                "contact": {
                    "last_name": "Rongsheng Zheng, doctor"
                }, 
                "facility": {
                    "address": {
                        "city": "Bengbu", 
                        "country": "China", 
                        "state": "Anhui"
                    }, 
                    "name": "The 1st affiliated hospital of bengbu medical college"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Jinwan Wang, doctor", 
                    "phone": "010-87788842"
                }, 
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing", 
                        "zip": "100021"
                    }, 
                    "name": "Cancer Institute and Hospital, Chinese Academy of Medical Sciences"
                }, 
                "investigator": [
                    {
                        "last_name": "Jianqiang Cai, doctor", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Jinwan Wang, doctor", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Yihebali Chi, doctor", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Xiaohui Niu, doctor"
                }, 
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing"
                    }, 
                    "name": "Beijing Jishuitan Hospital"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Zhiwei Fang, doctor"
                }, 
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing"
                    }, 
                    "name": "Beijing Cancer Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Jianchun Yu, doctor"
                }, 
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing"
                    }, 
                    "name": "Peking Union Medical College Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Wenzhi Bi, Doctor"
                }, 
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing", 
                        "zip": "100039"
                    }, 
                    "name": "Chinese PLA General Hospital"
                }, 
                "investigator": {
                    "last_name": "Wenzhi Bi, Doctor", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Zhiyong He, doctor"
                }, 
                "facility": {
                    "address": {
                        "city": "Fuzhou", 
                        "country": "China", 
                        "state": "Fujian"
                    }, 
                    "name": "Fujian Province Cancer Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Xia Zhu, doctor"
                }, 
                "facility": {
                    "address": {
                        "city": "Fuzhou", 
                        "country": "China", 
                        "state": "Fujian"
                    }, 
                    "name": "The First Affiliated Hospital of Fujian Meidical University"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Jianming Song, doctor"
                }, 
                "facility": {
                    "address": {
                        "city": "Lanzhou", 
                        "country": "China", 
                        "state": "Gansu"
                    }, 
                    "name": "Gansu Province Tumor Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Shusen Wang, doctor"
                }, 
                "facility": {
                    "address": {
                        "city": "Guangzhou", 
                        "country": "China", 
                        "state": "Guangdong"
                    }, 
                    "name": "Sun Yat-Sen University Cancer Center"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Yongkui Lu, doctor"
                }, 
                "facility": {
                    "address": {
                        "city": "Nanning", 
                        "country": "China", 
                        "state": "Guangxi"
                    }, 
                    "name": "Guangxi medical university affiliated tumor hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Guofan Qu, doctor"
                }, 
                "facility": {
                    "address": {
                        "city": "Harbin", 
                        "country": "China", 
                        "state": "Heilongjiang"
                    }, 
                    "name": "Harbin medical university affiliated tumor hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Ping Sun, doctor"
                }, 
                "facility": {
                    "address": {
                        "city": "Shenyang", 
                        "country": "China", 
                        "state": "Liaoning"
                    }, 
                    "name": "Liaoning Province Tumor Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Xiaonan Hong, doctor"
                }, 
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China", 
                        "state": "Shanghai"
                    }, 
                    "name": "Cancer Hospital of Fudan University"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Yang Yao, doctor"
                }, 
                "facility": {
                    "address": {
                        "city": "Shanghai", 
                        "country": "China", 
                        "state": "Shanghai"
                    }, 
                    "name": "Shanghai 6th People's Hospital"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Guowen Wang, doctor"
                }, 
                "facility": {
                    "address": {
                        "city": "Tianjin", 
                        "country": "China", 
                        "state": "Tianjin"
                    }, 
                    "name": "Tianjin Medical University Cancer Hospital"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase 2 Study of Anlotinib Hydrochloric Capsule in Advanced Soft Tissue Sarcoma", 
        "overall_contact": {
            "last_name": "Jinwan Wang, doctor", 
            "phone": "010-87788842"
        }, 
        "overall_contact_backup": {
            "last_name": "Yihebali Chi, doctor"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To evaluate the effectiveness of Anlotinib Hydrochloric Capsule by enhanced CT scan every two cycles. Refer to recist 1.1.", 
            "measure": "tumor size", 
            "safety_issue": "No", 
            "time_frame": "each 42 days  up to 48 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01878448"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "blood examination, urine examination, stool examination, blood biochemical (ALT, AST, TB(total bilirubin), DB, BUN, Cr, blood electrolyte), electrocardiogram (ecg), thyroid function, the function of blood coagulation, etc", 
            "measure": "Number of Participants with Adverse Events as a Measure of Safety and Tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "each 21 days  up to 48 months"
        }, 
        "source": "Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}